Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIM 23190

Drug Profile

BIM 23190

Alternative Names: BIM23190

Latest Information Update: 04 May 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomeasure Inc; Ipsen
  • Developer Ipsen
  • Class Antineoplastics; Oligopeptides; Piperazines
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 23 Jul 2003 BIM 23190 has been exclusively licensed to Teijin in Japan
  • 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 25 Sep 2002 Phase-II clinical trials in Diabetic retinopathy in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top